Department Of Allergology 1
1. Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021
2. Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria: A Cross-Sectional Study from Kazakhstan
3. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
4. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
5. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
6. Management of anaphylaxis due to COVID-19 vaccines in the elderly
7. Management of anaphylaxis due to COVID-19 vaccines in the elderly
8. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
9. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
10. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach – ARIA-EAACI Task Force Report
11. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
12. Unmet needs in hereditary angioedema: an international survey of physicians
13. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
14. Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife—CURE insights
15. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
16. A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
17. Pharmacoeconomic Analysis of Medicines Used for Bronchial Asthma in Children in Kazakhstan
18. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
19. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference
20. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study
21. Pharmacoeconomic research of medicines used for allergic rhinitis in children
1